clinical trial · NCT04317794
Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)
Biogen·—·active not recruiting·n = 74
Muscular Atrophy, SpinalNusinersen Sodium Injection
brief summary
The primary objective is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in Korea. The secondary objective is to evaluate the effectiveness of nusinersen sodium injection in the postmarketing setting in Korea.
started
Jul 2, 2019
primary completion
Feb 5, 2027
completion
Feb 5, 2027
last updated
Jul 17, 2025
official title
A Multicenter, Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) When Used in Routine Medical Practice in Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol